计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC 50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC 50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. Osilodrostat phosphate has blood pressure lowering ability. Osilodrostat phosphate can be used for research of Cushing syndrome (CS)
In Vitro
Osilodrostat (LCI699; 0.01-10 µM; HAC15 cells, 17 primary human adrenocortical cell cultures, and pituitary adenoma cells) phosphate inhibits cortisol and aldosterone. Osilodrostat results in inhibition of corticosterone, 11-deoxycortisol accumulation, and modest effects on adrenal androgens. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Osilodrostat (LCI699; 0.1-100 mg/kg; p.o.; once) phosphate inhibits aldosterone and corticosterone synthesis in Ang-II- and ACTH-stimulated Sprague Dawley rats . Osilodrostat (LCI699; 3-100 mg/kg; p.o.; daily, for 52 weeks) phosphate reduces mean arterial pressure and prolongs survival in dTG rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Ang-II- and ACTH-stimulated Sprague Dawley rats Dosage: 0.1, 0.3, 1 and 3 mg/kg (Ang-II-stimulated rats) and 1, 3, 10, 30 and 100 mg/kg (ACTH-stimulated rats) Administration: Oral administration; once Result: Inhibited the increase in plasma aldosterone concentrations stimulated by Ang II or ACTH in a dose-dependent manner. Animal Model: dTG rats Dosage: 3, 10, 30 and 100 mg/kg Administration: Oral administration; daily, for 52 weeks Result: Increased fractional LV (systolic and diastolic) shortening, normalized LV isovolumic relaxation time to RR (IVRT/RR) ratio and myocardial cell size and reduced LV weight in a dose-dependent manner.
Form:Solid
IC50& Target:IC50: 35 nM (CYP11B1), 0.7 nM (human aldosterone synthase), and 160 nM (rat aldosterone synthase)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 苯及其取代衍生物 |
| 亚类(Subclass) | 苯腈 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯腈 |
| 其他上位类(Alternative Parents) | 氟苯类 有机磷酸及其衍生物 N-取代咪唑 芳基氟化物 杂芳族化合物 腈类 氮杂环化合物 有机氟化物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 芳香族杂多环化合物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 吡唑 - 苯甲腈 - 碳腈 - 氰化物 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 咪唑 - N-取代咪唑 - 氰基化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机磷酸酯 - 有机氟化物 - 有机卤化物 - 有机杂环化合物 - 有机氮化合物 |
| 描述(Description) | 该化合物属于苯腈类有机化合物。这类化合物含有一个带有腈基取代基的苯环。 |
| 外部描述符(External Descriptors) | 暂无 |